RHOA and melanoma: Furthermore, Misek and collaborators recently showed that the activation of RhoA family GTPases is present in ~50–60% of melanoma Vemurafenib-resistant cell lines in vitro, reinforcing the idea that this signaling pathway has a key role in the achievement of aggressive features by melanoma cells [72].